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II. FEATURE MATRIX AND FEATURE SELECTION
Abstract—Adverse drug reaction (ADR) is widely
concerned for public health issue. In this study we
propose an original approach to detect the ADRs using
feature matrix and feature selection. The experiments
are carried out on the drug Atorvastatin. Major side
effects for the drug are detected and better performance
is achieved compared to other computerized methods.
The detected ADRs are based on the computerized
method, further investigation is needed.
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I. INTRODUCTION
Adverse drug reaction (ADR) is widely concerned for
public health issue. ADRs are one of most common causes to
withdraw some drugs from market [1 ]. Now two major
methods for detecting ADRs are spontaneous reporting system
(SRS) [ 2 , 3 ], and prescription event monitoring (PEM) [ 4 ,
5 ]. The World Health Organization (WHO) defines a signal
in pharmacovigilance as "any reported information on a
possible causal relationship between an adverse event and a
drug, the relationship being unknown or incompletely
documented previously"[6]. For spontaneous reporting
system, many machine learning methods are used to detect
ADRs, such as Bayesian confidence propagation neural
network (BCPNN) [7], decision support method [8], genetic
algorithm [9], knowledge based approach [10], etc. One
limitation is the reporting mechanism to submit ADR reports
[8], which has serious underreporting and is not able to
accurately quantify the corresponding risk. Another limitation
is hard to detect ADRs with small number of occurrences of
each drug-event association in the database.
In this paper we propose feature selection approach to
detect ADRs from The Health Improvement Network (THIN)
database. First feature matrix, which represents the medical
events for the patients before and after taking drugs, is created
by linking patients' prescriptions and corresponding medical
events together. Then significant features are selected based
on feature selection methods, comparing the feature matrix
before patients take drugs with one after patients take drugs.
Finally the significant ADRs can be detected from thousands
of medical events based on corresponding features.
Experiments are carried out on the drug Atorvastatin. Good
performance is achieved.
A. The Extraction of Feature Matrix
To detect the ADRs of drugs, first feature matrix is
extracted from THIN database, which describes the medical
events that patients occur before or after taking drugs. Then
feature selection method of Student's t-test is performed to
select the significant features from feature matrix containing
thousands of medical events. Figure 1 shows the process to
detect the ADRs using feature matrix. Feature matrix A
describes the medical events for each patient during 60 days
before they take drugs. Feature matrix B reflects the medical
events during 60 days after patients take drugs. In order to
reduce the effect of the small events, and save the
computation time and space, we set 100 patients as a group.
Matrix X and Y are feature matrix after patients are divided
into groups.
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Fig.l. The process to detect ADRs. Matrix A and B are
feature matrix before patients take drugs or after patients
take drugs. The time period of observation is set to 60 days.
Matrix X and Y are feature matrix after patients are divided
into groups. We set 100 patients as one group.
B. Medical Events and Readcodes
Medical events or symptoms are represented by medical
codes or Readcodes. There are 103387 types of medical
events in "Readcodes" database. The Read Codes used in
general practice (GP), were invented and developed by Dr
James Read in 1982. The NHS (National Health Service) has
expanded the codes to cover all areas of clinical practice.
The code is hierarchical from left to right or from level 1 to
level 5. It means that it gives more detailed information from
level 1 to level 5. Table 1 shows the medical symptoms
based on Readcodes at level 3 and at level 5. 'Other soft
tissue disorders' is general term using Readcodes at level 3.
`Foot pain', 'Heel pain', etc., give more details using
Readcodes at level 5.
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C. Feature Selection Based on Student's t-test
Feature extraction and feature selection are widely used
in biomedical data processing [11-17]. In our research we
use Student's t-test [18] feature selection method to detect
the significant ADRs from thousands of medical events.
Student's t-test is a kind of statistical hypothesis test based
on a normal distribution, and is used to measure the
difference between two kinds of samples. \
TABLE I MEDICAL EVENTS BASED ON READCODES AT LEVEL 3 AND
LEVEL 5.
Level Readcodes Medical events
Level 3 N24..00 Other soft tissue disorders
Muscle N245.16 Leg pain
pain N245111 Toe pain
Level 5 N245.13 Foot pain
N245700 Shoulder pain
N245.15 Heel pain
D. Other Parameters
The variable of ratio R1 is defined to evaluate significant
changes of the medical events, using ratio of the patient
number after taking the drug to one before taking the drug.
The variable R2 represents the ratio of patient number after
taking the drug to the number of whole population having
one particular medical symptom.
The ratio variables R1 and R2 are defined as follows:
IN B if NB # 0; (2)
NA if NB=0;
R2=NA I N
where NB and NA represent the numbers of patients
before or after they take drugs for having one particular
medical event respectively. The variable N represents the
number of whole population who take drugs.
III. EXPERIMENTS AND RESULTS
Atorvastatin [19], under the trade name Lipitor, is one of
the drugs known as statins. It is used for lowering blood
cholesterol. Drugs.com provides access to healthcare
information tailored for a professional audience, sourced
solely from the most trusted, well-respected and
independant agents such as the Food and Drug
Administration (FDA), American Society of Health-
System Pharmacists, Wolters Kluwer Health, Thomson
Micromedex, Cerner Multum and Stedman's. The side
effects for Atorvastatin [20] include dark urine, muscle
pain, tenderness, or weakness, painful, frequent urination,
redness, or swelling of a tendon or joint, swollen, blistered,
vomiting, stomach pain, unusual tiredness, and yellowing
of the eyes or skin, etc.
6803 patients are taking Atorvastatin from 20GPs data in
THIN database. Based on Readcodes at level 1-5, totally
10528 medical events are obtained before or after 6803
patients take the drug. So 6803x10528 feature matrix is
obtained. Based on Readcodes at level 1-3, we combine the
medical events, which have the same first three codes, into
one medical event. Totally 2350 medical events are
obtained, and 6803x2350 feature matrix are created. After
grouping them, 68x10528 and 68x2350 feature matrix are
formed to select the significant features, which reflect the
significant change of medical events.
Table 2 shows the top 20 detected results in ascending
order of p value of Student's t-test, using Readcodes at
level 1-5 and at level 1-3. The detected results are using p
value less than 0.05, which represent the significant
change after patients take the drug. Table 3 shows the
results in descending order of the ratio of the number of
patients after taking the drug to one before taking the drug.
Table 4 shows cancer information related to Atorvastatin.
The detected ADRs are based on our computerized
method, further investigation is needed.
It is clear that our detected results are consistent with
published side effects for statin drugs [20, 21]. Major ADRs
of 'muscle and musculoskeletal' events for statin drugs are
detected not only based on Readcodes at level 1-5, but also
based on Readcodes at level 1-3.
IV. CONCLUSIONS
In this study we propose a novel method to successfully
detect the ADRs using feature matrix and feature selection. A
feature matrix, which characterizes the medical events before
patients take drugs or after patients take drugs, is created
from THIN database. The feature selection method of
Student's t-test is used to detect the significant features from
thousands of medical events. The significant ADRs, which
are corresponding to significant features, are detected.
Experiments are performed on the drug Atorvastatin.
Compared to other computerized method, our proposed
method achieves good performance.
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TABLEII.THETOP 20ADRs FORATORVASTATIN BASED ONPVALUEOFSTUDENT'ST-TEST.
Rank Readcodes Medical events NB NA R1 R2
Level
1-5
1 1A55.00 Dysuria 26 181 6.96 2.66
2 1Z12.00 Chronic kidney disease stage 3 63 477 7.57 7.01
3 N131.00 Cervicalgia - pain in neck 73 337 4.62 4.95
4 N143.00 Sciatica 48 205 4.27 3.01
5 F4C0.00 Acute conjunctivitis 60 274 4.57 4.03
6 N245.17 Shoulder pain 99 376 3.80 5.53
7 M03z000 Cellulitis NOS 57 264 4.63 3.88
8 1C14.00 'Blocked ear" 13 120 9.23 1.76
9 A53..11 Shingles 17 121 7.12 1.78
10 H01..00 Acute sinusitis 44 194 4.41 2.85
11 1M10.00 Knee pain 103 369 3.58 5.42
12 19EA.00 Change in bowel habit 17 102 6.00 1.50
13 H06z000 Chest infection NOS 136 563 4.14 8.28
14 Cl OF.00 Type 2 diabetes mellitus 154 436 2.83 6.41
15 1D14.00 C/O: a rash 70 357 5.10 5.25
16 M0...00 Skin and subcutaneous tissue infections 18 115 6.39 1.69
17 N247100 Leg cramps 36 132 3.67 1.94
18 M111.00 Atopic dermatitis/eczema 36 190 5.28 2.79
19 19F..00 Diarrhoea symptoms 52 244 4.69 3.59
20 H33..00 Asthma 23 106 4.61 1.56
Level
1-3
1 171..00 Cough 309 1105 3.58 16.24
2 N21..00 Peripheral enthesopathies and allied
syndromes
136 568 4.18 8.35
3 N24..00 Other soft tissue disorders 462 1371 2.97 20.15
4 1Z1..00 Chronic renal impairment 79 570 7.22 8.38
5 1B1..00 General nervous symptoms 204 667 3.27 9.80
6 19F..00 Diarrhoea symptoms 97 444 4.58 6.53
7 M22..00 Other dermatoses 94 353 3.76 5.19
8 1C1..00 Hearing symptoms 43 269 6.26 3.95
9 183..00 Oedema 97 433 4.46 6.36
10 N13..00 Other cervical disorders 81 362 4.47 5.32
11 1B8..00 Eye symptoms 73 322 4.41 4.73
12 F4C..00 Disorders of conjunctiva 85 381 4.48 5.60
13 H06..00 Acute bronchitis and bronchiolitis 357 1161 3.25 17.07
14 173..00 Breathlessness 198 675 3.41 9.92
15 1A5..00 Genitourinary pain 56 276 4.93 4.06
16 M03..00 Other cellulitis and abscess 73 357 4.89 5.25
17 N09..00 Other and unspecified joint disorders 196 721 3.68 10.60
18 1D1..00 C/O: a general symptom 159 695 4.37 10.22
19 A53..00 Herpes zoster 20 158 7.90 2.32
20 J57..00 Other disorders of intestine 48 222 4.63 3.26
Variable NB and NA represent the numbers of patients before or after they take drugs for having one particular medical event. Variable R1represents the ratio of the
numbers of patients after taking drugs to the numbers of patients before taking drugs. Variable R2 represents the ratio of the numbers of patients after taking drugs to
the number of the whole population.
TABLEIII.THETOP20ADRSFORATORVASTATINBASEDONDESCENDINGORDEROFR1VALUE.
Rank Readcodes Medical events NB NA R1 R2
Level 1-5
1 M03z100 Abscess NOS 1 39 39.00 0.57
2 1922.00 Sore mouth 1 29 29.00 0.43
3 173K.00 MRC Breathlessness Scale: grade 4 1 28 28.00 0.41
4 F420600 Non proliferative diabetic retinopathy 1 28 28.00 0.41
5 M22z.11 Actinic keratosis 1 27 27.00 0.40
6 564..13 Head injury 1 24 24.00 0.35
7 Sz...00 Injury and poisoning NOS 1 24 24.00 0.35
216
8 G843.00 External haemorrhoids, simple 0 22 22.00 0.32
9 J570100 Rectal polyp 1 22 22.00 0.32
10 C10FL00 Type 2 diabetes mellitus with persistent proteinuria 0 22 22.00 0.32
11 G5yy900 Left ventricular systolic dysfunction 1 22 22.00 0.32
12 J681.00 Melaena 0 21 21.00 0.31
13 11060.11 Acute wheezy bronchitis 1 21 21.00 0.31
14 N141.00 Pain in thoracic spine 1 21 21.00 0.31
15 N216500 Prepatellar bursitis 1 20 20.00 0.29
16 F4C0311 Sticky eye 1 20 20.00 0.29
17 1M00.00 Pain in elbow 1 20 20.00 0.29
18 N211300 Supraspinatus tendinitis 1 20 20.00 0.29
19 J680.00 Haematemesis 1 19 19.00 0.28
20 F425.00 Degeneration of macula and posterior pole 1 19 19.00 0.28
Level 1-3
1 1J0..00 Suspected malignancy 0 28 28.00 0.41
2 BB2..00 [M]Papillary and squamous cell neoplasms 0 24 24.00 0.35
3 1M0..00 Pain in upper limb 1 24 24.00 0.35
4 S3z..00 Fracture of unspecified bones 1 24 24.00 0.35
5 Sz...00 Injury and poisoning NOS 1 24 24.00 0.35
6 J68..00 Gastrointestinal haemorrhage 3 54 18.00 0.79
7 SD9..00 Superficial injuries of multiple and unspecified sites 0 18 18.00 0.26
8 J04..00 Dentofacial anomalies 1 17 17.00 0.25
9 D01..00 Other deficiency anaemias 2 33 16.50 0.49
10 J07..00 Salivary gland diseases 1 16 16.00 0.24
11 C35..00 Disorders of mineral metabolism 1 16 16.00 0.24
12 M08..00 Cutaneous cellulitis 2 29 14.50 0.43
13 G86..00 Noninfective lymphatic disorders 0 14 14.00 0.21
14 J03..00 Gingival and periodontal disease 1 14 14.00 0.21
15 172..00 Blood in sputum - haemoptysis 2 26 13.00 0.38
16 PI13..00 Other specified skin anomalies 0 12 12.00 0.18
17 535..00 Fracture of one or more tarsal and metatarsal bones 0 12 12.00 0.18
18 J67..00 Diseases of pancreas 1 12 12.00 0.18
19 SD7..00 Superficial injury of foot and toe(s) 1 12 12.00 0.18
20 D31..00 Purpura and other haemorrhagic conditions 1 12 12.00 0.18
TABLEW.THEPOTENTIALADRSRELATEDTOCANCERFOR ATORVASTATIN BASED ONPVALUEOFSTUDENT'ST-TEST.
Rank Readcodes Medical events NB NA R1
1 B33..00 Other malignant neoplasm of skin 18 97 5.39 1.43
2 B76..00 Benign neoplasm of skin 52 139 2.67 2.04
3 1J0..00 Suspected malignancy 0 28 28.00 0.41
4 B46..00 Malignant neoplasm of prostate 8 46 5.75 0.68
5 BB2..00 [M]Papillary and squamous cell neoplasms 0 24 24.00 0.35
6 B34..00 Malignant neoplasm of female breast 4 26 6.50 0.38
7 BB5..00 [M]Adenomas and adenocarcinomas 6 28 4.67 0.41
8 B13..00 Malignant neoplasm of colon 3 20 6.67 0.29
9 B14..00 Malignant neoplasm of rectum, rectosigmoid junction and anus 0 9 9.00 0.13
10 B8...00 Carcinoma in situ 3 19 6.33 0.28
11 B83..00 Carcinoma in situ of breast and genitourinary system 7 21 3.00 0.31
12 BB4..00 [M]Transitional cell papillomas and carcinomas 0 7 7.00 0.10
13 B49..00 Malignant neoplasm of urinary bladder 2 11 5.50 0.16
14 B22..00 Malignant neoplasm of trachea, bronchus and lung 2 15 7.50 0.22
15 B10..00 Malignant neoplasm of oesophagus 1 10 10.00 0.15
16 B57..00 Secondary malig neop of respiratory and digestive systems 0 6 6.00 0.09
17 BB3..00 [M]Basal cell neoplasms 4 19 4.75 0.28
18 B58..00 Secondary malignant neoplasm of other specified sites 0 9 9.00 0.13
19 B59..00 Malignant neoplasm of unspecified site 0 5 5.00 0.07
20 B21..00 Malignant neoplasm of larynx 0 5 5.00 0.07
21 BB8..00 [M]Cystic, mucinous and serous neoplasms 0 5 5.00 0.07
22 B11..00 Malignant neoplasm of stomach 1 7 7.00 0.10
23 B4A..00 Malig neop of kidney and other unspecified urinary organs 0 6 6.00 0.09
24 B7F..00 Benign neoplasm of brain and other parts of nervous system 0 6 6.00 0.09
25 BB1..00 [M]Epithelial neoplasms NOS 2 10 5.00 0.15
26 B71..00 Benign neoplasm of other parts of digestive system 4 11 2.75 0.16
27 B812.00 Carcinoma in situ of bronchus and lung 0 2 2.00 0.03
28 BBK..00 [M]Myomatous neoplasms 0 2 2.00 0.03
29 B440.00 Malignant neoplasm of ovary 0 2 2.00 0.03
30 BBMz.00 [M]Fibroepithelial neoplasm NOS 0 2 2.00 0.03
